Seletracetam lithium bromide Bioactivity,Chemical Properties,Storage & Solubility Information Pathways-PeptideDB

Description	Seletracetam (Ucb 44212) lithium bromide is a SV2A modulator, intended for epilepsy research. It is an analog of Levetiracetam, an antiepileptic agent.
In vitro	Seletracetam displays one-log-unit higher affinity (pKi=7.1) than Levetiracetam (6.1) to the LEV-binding site[2]. Seletracetam lithium bromide inhibits high-voltage-activated Ca 2+ currents and intracellular Ca 2+ increase in rat cortical neurons in vitro[2]. Seletracetam (1-10 μM) lithium bromide reduces both the amplitude and repetitive firing of population spikes induced by a high K + /low Ca 2+ concentration fluid (HKLCF) in rat hippocampal slices[3].
In vivo	Seletracetam (intraperitoneal injection) lithium bromide displays potent protection against secondary generalised motor seizures in fully corneally-kindled mice (ED 50 0.31 mg/kg). In audiogenic seizure susceptible mice, Seletracetam (i.p) protects against clonic convulsion expression with an ED 50 of 0.17 mg/kg[3]. Seletracetam (0.0074 mg/kg to 74 mg/kg; intraperitoneal injection) lithium bromide increases the generalized seizure threshold current and decreases the duration of the after-discharge and the seizure severity observed at the after-discharge threshold current, and generally has a much more potent effect than previously observed for Levetiracetam[3]. Animal Model: Female Wistar rats (200-220 g) (Amygdala-kindled rats)[3]Dosage: 0.0074,7.4, 74 mg/kg Administration: Intraperitoneal injection; 60 min before seizure threshold determination Result: Markedly increased the generalized seizure threshold at all doses tested, with increases of 190% (0.0074 mg/kg), 302% (0.074 mg/kg), 429% (0.74 mg/kg), 433% (7.4 mg/kg) and 679% (74 mg/kg).
Synonyms	Ucb 44212 lithium bromide
molecular weight	319.07
Molecular formula	C10H14BrF2LiN2O2
CAS	2024584-38-9
Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year
References	1. Pollard JR, et al. Seletracetam, a small molecule SV2A modulator for the treatment of epilepsy. Curr Opin Investig Drugs. 2008 Jan;9(1):101-7. 2. Martella G, et al. Seletracetam (ucb 44212) inhibits high-voltage-activated Ca2+ currents and intracellular Ca2+ increase in rat cortical neurons in vitro. Epilepsia. 2009 Apr;50(4):702-10. 3. Matagne A, et al. Profile of the new pyrrolidone derivative seletracetam (ucb 44212) in animal models of epilepsy. Eur J Pharmacol. 2009;614(1-3):30-37.

PeptideDB

Seletracetam lithium bromide

CAS No.: 2024584-38-9